CM
CMPX icon

Caption Management’s Compass Therapeutics CMPX Stock Holding History

Caption Management’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-2,493,500
Closed -$6.48M – 1712
2025
Q2 		$6.48M Buy
+2,493,500
New +$5.14M 0.07% 326

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Caption Management's CMPX Position: Q2 2026 in Review

Caption Management opened a new position in Compass Therapeutics (CMPX) in Q2 2026: 263,577 shares worth $577K. The stake represents ﹤0.01% of the portfolio and ranks #1291 among its holdings. This is a return to the name: Caption Management previously reported a position in CMPX as recently as Q3 2025.

Caption Management first reported a position in CMPX in Q2 2025 and has held it in 3 quarters since. The position peaked at $1.89M in Q2 2025. 215 funds tracked by Wall St. Rank hold CMPX as of Q2 2026.

  • Caption Management held 263,577 shares of Compass Therapeutics worth $577K as of Q2 2026.
  • Compass Therapeutics was a new Caption Management position in Q2 2026.
  • Compass Therapeutics made up ﹤0.01% of Caption Management's portfolio in Q2 2026, its #1291 holding.
  • Caption Management first reported a position in Compass Therapeutics in Q2 2025 and has held it in 3 quarters since.
  • Caption Management's Compass Therapeutics position peaked at $1.89M in Q2 2025.
  • 215 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2026.

Based on Caption Management's 13F filing for Q2 2026, filed 14 Aug 2026.